UBS Group’s 4D Pharma PLC Warrant LBPSW Stock Holding History

UBS Group’s Portfolio LBPSW Stock Details LBPSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,130	Closed	-$1K	–	11619
2022 Q1	$1K	Buy	3,130 +1,810	+137%	+$750	﹤0.01%	10127
2021 Q4	$1K	Buy	+1,320	New	+$915	﹤0.01%	10189
2021 Q2	–	Sell	-4,845	Closed	-$5K	–	10179
2021 Q1	$5K	Buy	+4,845	New	+$6.06K	﹤0.01%	8370

Other funds holding LBPSW

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

UBS Group's LBPSW Position: Q2 2022 in Review

UBS Group sold out of 4D Pharma PLC Warrant (LBPSW) in Q2 2022, closing a stake of 3,130 shares — an estimated $1K sold.

UBS Group first reported a position in LBPSW in Q1 2021 and held it in 3 quarters. The position peaked at $5K in Q1 2021. 4 funds tracked by Wall St. Rank hold LBPSW as of Q2 2022.

UBS Group reported no remaining 4D Pharma PLC Warrant position as of Q2 2022 after selling out during the quarter.
UBS Group sold 3,130 4D Pharma PLC Warrant shares in Q2 2022, an estimated $1K.
UBS Group first reported a position in 4D Pharma PLC Warrant in Q1 2021 and held it in 3 quarters.
UBS Group's 4D Pharma PLC Warrant position peaked at $5K in Q1 2021.
4 funds tracked by Wall St. Rank held 4D Pharma PLC Warrant as of Q2 2022.

Based on UBS Group's 13F filing for Q2 2022, filed 10 Aug 2022.